Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Angiodynamics (ANGO) over the last 15 years, with Q4 2025 value amounting to $6.7 million.

  • Angiodynamics' Other Accumulated Expenses fell 2508.36% to $6.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $6.7 million, marking a year-over-year decrease of 2508.36%. This contributed to the annual value of $7.4 million for FY2025, which is 250.73% down from last year.
  • Per Angiodynamics' latest filing, its Other Accumulated Expenses stood at $6.7 million for Q4 2025, which was down 2508.36% from $8.7 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Other Accumulated Expenses ranged from a high of $10.3 million in Q1 2024 and a low of $1.8 million during Q4 2023
  • In the last 5 years, Angiodynamics' Other Accumulated Expenses had a median value of $2.6 million in 2022 and averaged $4.5 million.
  • In the last 5 years, Angiodynamics' Other Accumulated Expenses surged by 40879.18% in 2024 and then tumbled by 4388.34% in 2025.
  • Angiodynamics' Other Accumulated Expenses (Quarter) stood at $2.6 million in 2021, then rose by 0.66% to $2.6 million in 2022, then plummeted by 31.83% to $1.8 million in 2023, then soared by 408.79% to $9.0 million in 2024, then dropped by 25.08% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q4 2025, $8.7 million for Q3 2025, and $7.4 million during Q2 2025.